<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Jupiter Neurosciences, Inc. Common Stock — News on 6ix</title>
<link>https://6ix.com/company/jupiter-neurosciences-inc-common-stock</link>
<description>Latest news and press releases for Jupiter Neurosciences, Inc. Common Stock on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Tue, 07 Apr 2026 04:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/jupiter-neurosciences-inc-common-stock" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo68358d0b78dffbe2df100b91.webp</url>
<title>Jupiter Neurosciences, Inc. Common Stock</title>
<link>https://6ix.com/company/jupiter-neurosciences-inc-common-stock</link>
</image>
<item>
<title>Jupiter Neurosciences Appoints Kristopher Fishman and Sanjiv Lal to Nugevia™ Advisory Board</title>
<link>https://6ix.com/company/jupiter-neurosciences-inc-common-stock/news/jupiter-neurosciences-appoints-kristopher-fishman-and-sanjiv-lal-to-nugeviatm-advisory-board</link>
<guid isPermaLink="true">https://6ix.com/company/jupiter-neurosciences-inc-common-stock/news/jupiter-neurosciences-appoints-kristopher-fishman-and-sanjiv-lal-to-nugeviatm-advisory-board</guid>
<pubDate>Tue, 07 Apr 2026 04:00:00 GMT</pubDate>
<description>New Advisors Bring Nationwide Pharmacy and Wellness Distribution Expertise to Nugevia™ Consumer Longevity Line Compounding Pharmacy and Wellness Channels</description>
</item>
<item>
<title>Jupiter Neurosciences to Present at Emerging Growth Conference on April 2</title>
<link>https://6ix.com/company/jupiter-neurosciences-inc-common-stock/news/jupiter-neurosciences-to-present-at-emerging-growth-conference-on-april-2-6</link>
<guid isPermaLink="true">https://6ix.com/company/jupiter-neurosciences-inc-common-stock/news/jupiter-neurosciences-to-present-at-emerging-growth-conference-on-april-2-6</guid>
<pubDate>Tue, 31 Mar 2026 04:00:00 GMT</pubDate>
<description>JUPITER, FL, March 31, 2026 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS) (“Jupiter” or the “Company”), a clinical-stage pharmaceutical</description>
</item>
<item>
<title>Jupiter Neurosciences to Present at BIO Investment and Growth Summit 2026</title>
<link>https://6ix.com/company/jupiter-neurosciences-inc-common-stock/news/jupiter-neurosciences-to-present-at-bio-investment-and-growth-summit-2026</link>
<guid isPermaLink="true">https://6ix.com/company/jupiter-neurosciences-inc-common-stock/news/jupiter-neurosciences-to-present-at-bio-investment-and-growth-summit-2026</guid>
<pubDate>Mon, 02 Mar 2026 05:00:00 GMT</pubDate>
<description>Advancing FDA-Cleared Phase IIa Parkinson’s Program Targeting Neuroinflammation Dual-Path Strategy Combines Clinical Development with Revenue-Generating</description>
</item>
<item>
<title>Jupiter Neurosciences Invited to Present Clinical and Commercial Progress at Investor Dinner at Mar-a-Lago</title>
<link>https://6ix.com/company/jupiter-neurosciences-inc-common-stock/news/jupiter-neurosciences-invited-to-present-clinical-and-commercial-progress-at-investor-dinner-at-mar-a-lago</link>
<guid isPermaLink="true">https://6ix.com/company/jupiter-neurosciences-inc-common-stock/news/jupiter-neurosciences-invited-to-present-clinical-and-commercial-progress-at-investor-dinner-at-mar-a-lago</guid>
<pubDate>Wed, 25 Feb 2026 13:30:00 GMT</pubDate>
<description>Jupiter Neurosciences, Inc. Jupiter Neurosciences Invited to Present Clinical and Commercial Progress at Investor Dinner at Mar-a-Lago JUPITER, FL, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS) ("Jupiter" or the "Company"), a clinical-stage pharmaceutical company focused on neuroinflammation and central nervous system disorders, announces that members of senior management have been invited, as the only company this evening, to present its progress at a private inve</description>
</item>
<item>
<title>Jupiter Neurosciences Amends Yorkville Installment Provisions to Align Capital With Clinical and Commercial Execution</title>
<link>https://6ix.com/company/jupiter-neurosciences-inc-common-stock/news/jupiter-neurosciences-amends-yorkville-installment-provisions-to-align-capital-with-clinical-and-commercial-execution</link>
<guid isPermaLink="true">https://6ix.com/company/jupiter-neurosciences-inc-common-stock/news/jupiter-neurosciences-amends-yorkville-installment-provisions-to-align-capital-with-clinical-and-commercial-execution</guid>
<pubDate>Mon, 23 Feb 2026 14:30:00 GMT</pubDate>
<description>Repayment Commencement Deferred to April 1, 2026 Core Economic Terms of $6.0 Million Financing Remain Unchanged JUPITER, FL, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS), a clinical-stage pharmaceutical company focused on neuroinflammation and central nervous system disorders, today announced that it has entered into an Omnibus Amendment with YA II PN, Ltd. modifying the installment payment provisions of its previously disclosed Convertible Promissory Notes issued</description>
</item>
<item>
<title>Jupiter Neurosciences Selected as B2i Digital Featured Company</title>
<link>https://6ix.com/company/jupiter-neurosciences-inc-common-stock/news/jupiter-neurosciences-selected-as-b2i-digital-featured-company</link>
<guid isPermaLink="true">https://6ix.com/company/jupiter-neurosciences-inc-common-stock/news/jupiter-neurosciences-selected-as-b2i-digital-featured-company</guid>
<pubDate>Thu, 12 Feb 2026 05:00:00 GMT</pubDate>
<description>Clinical-Stage Pharmaceutical Company Advancing Phase IIa Parkinson's Trial Dual-Path Strategy Targets Neuroinflammation While Expanding Nugevia(TM) Longevity</description>
</item>
<item>
<title>Jupiter Neurosciences Expands Nugevia™ Addressable Market with Focus on GLP-1 Users</title>
<link>https://6ix.com/company/jupiter-neurosciences-inc-common-stock/news/jupiter-neurosciences-expands-nugevia-addressable-110000663</link>
<guid isPermaLink="true">https://6ix.com/company/jupiter-neurosciences-inc-common-stock/news/jupiter-neurosciences-expands-nugevia-addressable-110000663</guid>
<pubDate>Wed, 28 Jan 2026 11:00:00 GMT</pubDate>
<description>Nugevia™ supports metabolic, mitochondrial, and neuroinflammatory biology impacted by GLP-1-driven weight loss Jupiter, Florida, Jan. 28, 2026 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS) (“Jupiter” or the “Company”), a clinical-stage pharmaceutical company developing JOTROL™, a patented resveratrol-based platform, today announced a strategic initiative to support individuals using GLP-1-based weight loss therapies through its Nugevia™ consumer longevity product line. This init</description>
</item>
<item>
<title>Jupiter Neurosciences Presenting at the 3rd Annual DealFlow Discovery Conference</title>
<link>https://6ix.com/company/jupiter-neurosciences-inc-common-stock/news/jupiter-neurosciences-presenting-3rd-annual-154500539</link>
<guid isPermaLink="true">https://6ix.com/company/jupiter-neurosciences-inc-common-stock/news/jupiter-neurosciences-presenting-3rd-annual-154500539</guid>
<pubDate>Tue, 27 Jan 2026 15:45:00 GMT</pubDate>
<description>JUPITER, FL / ACCESS Newswire / January 27, 2026 / Jupiter Neurosciences, Inc. (NASDAQ:JUNS), a clinical-stage pharmaceutical company developing JOTROL™, a patented resveratrol-based platform for neuroinflammation and healthy aging, today announced ...</description>
</item>
<item>
<title>Join Jupiter Neurosciences’ Exclusive Live Investor Webinar and Q&A Session on January 6</title>
<link>https://6ix.com/company/jupiter-neurosciences-inc-common-stock/news/join-jupiter-neurosciences-exclusive-live-130000830</link>
<guid isPermaLink="true">https://6ix.com/company/jupiter-neurosciences-inc-common-stock/news/join-jupiter-neurosciences-exclusive-live-130000830</guid>
<pubDate>Tue, 23 Dec 2025 13:00:00 GMT</pubDate>
<description>Jupiter, Florida, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS) (“Jupiter” or the “Company”), a clinical-stage pharmaceutical company developing JOTROL™, a patented resveratrol-based platform, is pleased to invite investors to a webinar on January 6, 2026, at 4:15 p.m. ET. The exclusive event, hosted by RedChip Companies, will feature Jupiter Neuroscience Chairman and CEO Chister Rosén who will provide investors with an overview of Jupiter Neurosciences’ scientific</description>
</item>
<item>
<title>Jupiter Neurosciences Marks Transformational First Year as a Public Company, Entering 2026 with Powerful Clinical and Commercial Momentum</title>
<link>https://6ix.com/company/jupiter-neurosciences-inc-common-stock/news/jupiter-neurosciences-marks-transformational-first-130000175</link>
<guid isPermaLink="true">https://6ix.com/company/jupiter-neurosciences-inc-common-stock/news/jupiter-neurosciences-marks-transformational-first-130000175</guid>
<pubDate>Wed, 03 Dec 2025 13:00:00 GMT</pubDate>
<description>Company advances JOTROL™ into Phase 2a Parkinson’s trial, launches Nugevia™ consumer brand, and strengthens financial position Jupiter, Florida, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS) (“Jupiter” or the “Company”), a clinical-stage pharmaceutical company developing JOTROL™, a patented resveratrol-based platform, today announced the publication of a shareholder letter from Chairman and CEO Christer Rosén marking Jupiter’s first full year as a public company an</description>
</item>
<item>
<title>Jupiter Neurosciences to Participate in NobleCon21</title>
<link>https://6ix.com/company/jupiter-neurosciences-inc-common-stock/news/jupiter-neurosciences-participate-noblecon21-211500747</link>
<guid isPermaLink="true">https://6ix.com/company/jupiter-neurosciences-inc-common-stock/news/jupiter-neurosciences-participate-noblecon21-211500747</guid>
<pubDate>Tue, 02 Dec 2025 21:15:00 GMT</pubDate>
<description>Jupiter, Florida--(Newsfile Corp. - December 2, 2025) - Jupiter Neurosciences, Inc. (NASDAQ: JUNS), a clinical-stage pharmaceutical company developing JOTROL™, a patented resveratrol-based therapeutic platform targeting neuroinflammation and mitochondrial dysfunction, today announced that its management team will present at the upcoming Noble Capital Markets' 21st Annual Emerging Growth Equity Conference on December 2-3, 2025, in Boca Raton, FL.Held annually in South Florida, NobleCon brings...</description>
</item>
<item>
<title>Jupiter Neurosciences Brings Its Brain Health Expertise To The Masses With Nugevia - And A Range Of Celebs From Athletes To Scientists Are Customers</title>
<link>https://6ix.com/company/jupiter-neurosciences-inc-common-stock/news/jupiter-neurosciences-brings-its-brain-health-expertise-to-the-masses-with-nugevia-and-a-range-of-celebs-from-athletes-to-scientists-are-customers</link>
<guid isPermaLink="true">https://6ix.com/company/jupiter-neurosciences-inc-common-stock/news/jupiter-neurosciences-brings-its-brain-health-expertise-to-the-masses-with-nugevia-and-a-range-of-celebs-from-athletes-to-scientists-are-customers</guid>
<pubDate>Thu, 06 Nov 2025 05:00:00 GMT</pubDate>
<description>By Meg Flippin Benzinga DETROIT, MICHIGAN - November 6, 2025 (NEWMEDIAWIRE) - When it comes to brain health, Jupiter Neurosciences Inc. (NASDAQ: JUNS) knows a</description>
</item>
<item>
<title>Jupiter Neurosciences Receives FDA Clearance of IND Application to Initiate Phase 2a Clinical Trial of JOTROL™ in Parkinson’s Disease</title>
<link>https://6ix.com/company/jupiter-neurosciences-inc-common-stock/news/jupiter-neurosciences-receives-fda-clearance-133000472</link>
<guid isPermaLink="true">https://6ix.com/company/jupiter-neurosciences-inc-common-stock/news/jupiter-neurosciences-receives-fda-clearance-133000472</guid>
<pubDate>Wed, 05 Nov 2025 13:30:00 GMT</pubDate>
<description>Jupiter, Florida, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ:JUNS), a clinical-stage pharmaceutical company developing JOTROL™, a patented resveratrol-based therapeutic platform targeting neuroinflammation and mitochondrial dysfunction, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application to initiate a Phase 2a clinical trial of JOTROL™ in patients with Parkinson’s disease. The FDA’s clearance marks</description>
</item>
<item>
<title>Jupiter Neurosciences Enters into Agreements for up to $20 Million in Flexible Financing</title>
<link>https://6ix.com/company/jupiter-neurosciences-inc-common-stock/news/jupiter-neurosciences-enters-agreements-20-123000514</link>
<guid isPermaLink="true">https://6ix.com/company/jupiter-neurosciences-inc-common-stock/news/jupiter-neurosciences-enters-agreements-20-123000514</guid>
<pubDate>Mon, 27 Oct 2025 12:30:00 GMT</pubDate>
<description>Financing designed to support Phase 2 Parkinson’s trial and accelerate Nugevia™ product line growth Jupiter, FL, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc (“JUNS” or the “Company”) (NASDAQ: JUNS), a clinical stage biopharmaceutical company that is advancing a therapeutic pipeline targeting central nervous system (“CNS”) disorders, while also expanding into the consumer longevity market with its Nugevia™ product line, today announced that it has entered into two strategic finan</description>
</item>
<item>
<title>Jupiter Neurosciences Names Visionary Entrepreneur and Biohacker Jean Fallacara as Third Nugevia™ Brand Ambassador</title>
<link>https://6ix.com/company/jupiter-neurosciences-inc-common-stock/news/jupiter-neurosciences-names-visionary-entrepreneur-120000622</link>
<guid isPermaLink="true">https://6ix.com/company/jupiter-neurosciences-inc-common-stock/news/jupiter-neurosciences-names-visionary-entrepreneur-120000622</guid>
<pubDate>Mon, 15 Sep 2025 12:00:00 GMT</pubDate>
<description>Partnership strengthens Nugevia™ launch bringing clinical and scientific integrity to the fast-growing longevity space Jupiter, Florida, Sept. 15, 2025 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ:JUNS) today announced that Jean Fallacara, visionary entrepreneur, neuroscientist, and internationally recognized biohacker, has joined the Company as the third official brand ambassador for Nugevia™, Jupiter Neurosciences’ new consumer longevity supplement line. Visionary entrepreneur and b</description>
</item>
<item>
<title>Jupiter Neurosciences Launches Nugevia™ Website and Opens Pre-Orders for Groundbreaking Longevity Supplements</title>
<link>https://6ix.com/company/jupiter-neurosciences-inc-common-stock/news/jupiter-neurosciences-launches-nugevia-website-120000073</link>
<guid isPermaLink="true">https://6ix.com/company/jupiter-neurosciences-inc-common-stock/news/jupiter-neurosciences-launches-nugevia-website-120000073</guid>
<pubDate>Tue, 26 Aug 2025 12:00:00 GMT</pubDate>
<description>Targeting the Multi-Trillion Dollar Longevity Market Jupiter, Florida, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS) (“Jupiter” or the “Company”), a clinical-stage pharmaceutical company pioneering therapies for central nervous system (CNS) disorders and advancing science-based consumer health solutions, today announced a pivotal expansion of its dual-path business model with the launch of its dedicated Nugevia™ e-commerce website, www.nugevia.com, and the opening</description>
</item>
<item>
<title>Jupiter Neurosciences Names NBA Legend Chris Webber as Second Nugevia™ Brand Ambassador</title>
<link>https://6ix.com/company/jupiter-neurosciences-inc-common-stock/news/jupiter-neurosciences-names-nba-legend-121200565</link>
<guid isPermaLink="true">https://6ix.com/company/jupiter-neurosciences-inc-common-stock/news/jupiter-neurosciences-names-nba-legend-121200565</guid>
<pubDate>Tue, 19 Aug 2025 12:12:00 GMT</pubDate>
<description>Partnership expands momentum for launch of new longevity supplement line powered by clinical science and performance-driven innovation Jupiter, Florida, Aug. 19, 2025 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS) today announced that Chris Webber, five-time NBA All-Star and Hall of Fame inductee, has joined the Company as the second official brand ambassador for Nugevia™, Jupiter Neurosciences’ new consumer longevity supplement line. Webber, who played 15 seasons in the National</description>
</item>
<item>
<title>Longevity In A Capsule: Jupiter Neurosciences Launches First Three Supplements Under Nugevia(TM) Brand</title>
<link>https://6ix.com/company/jupiter-neurosciences-inc-common-stock/news/longevity-in-a-capsule-jupiter-neurosciences-launches-first-three-supplements-under-nugeviatm-brand</link>
<guid isPermaLink="true">https://6ix.com/company/jupiter-neurosciences-inc-common-stock/news/longevity-in-a-capsule-jupiter-neurosciences-launches-first-three-supplements-under-nugeviatm-brand</guid>
<pubDate>Tue, 19 Aug 2025 04:00:00 GMT</pubDate>
<description>By Meg Flippin Benzinga DETROIT, MICHIGAN - August 19, 2025 (NEWMEDIAWIRE) - Jupiter Neurosciences Inc. (NASDAQ: JUNS), a clinical-stage pharmaceutical</description>
</item>
<item>
<title>Jupiter Neurosciences Introduces Nugevia™ MND: A Cognitive Health Supplement Leveraging Clinically Validated Neuroscience</title>
<link>https://6ix.com/company/jupiter-neurosciences-inc-common-stock/news/jupiter-neurosciences-introduces-nugevia-mnd-120000788</link>
<guid isPermaLink="true">https://6ix.com/company/jupiter-neurosciences-inc-common-stock/news/jupiter-neurosciences-introduces-nugevia-mnd-120000788</guid>
<pubDate>Mon, 11 Aug 2025 12:00:00 GMT</pubDate>
<description>MND combines proprietary resveratrol-based platform and NovaSOL® Curcumin to enhance cognitive performance and support neuroprotective health Jupiter, Florida, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS) ("Jupiter" or the "Company"), a clinical-stage pharmaceutical company developing JOTROL™, a patented resveratrol-based platform, today introduced Nugevia™ MND, a scientifically formulated supplement designed to protect and enhance cognitive function and support o</description>
</item>
<item>
<title>Jupiter Neurosciences Highlights Critical Advancement of JOTROL™ Over Traditional Resveratrol with Breakthrough Bioavailability and CNS-Targeted Science</title>
<link>https://6ix.com/company/jupiter-neurosciences-inc-common-stock/news/jupiter-neurosciences-highlights-critical-advancement-120000739</link>
<guid isPermaLink="true">https://6ix.com/company/jupiter-neurosciences-inc-common-stock/news/jupiter-neurosciences-highlights-critical-advancement-120000739</guid>
<pubDate>Wed, 23 Jul 2025 12:00:00 GMT</pubDate>
<description>Transforming a promising molecule into a clinically viable therapeutic platform Jupiter, Florida, July 23, 2025 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS) ("Jupiter" or the "Company"), a clinical-stage pharmaceutical company developing JOTROL™, a patented resveratrol-based platform, spotlights the scientific and clinical advantages of its proprietary resveratrol platform, JOTROL™, over conventional resveratrol formulations. Unlocking Resveratrol’s Therapeutic Promise Resverat</description>
</item>
</channel>
</rss>